Office for Technology Commercialization

Antagomir to prevent cardiac arrhythmia

Technology #2019-069

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Sam Dudley, MD, PhD
Professor of Medicine, Cardiovascular Division, Medical School
External Link (
Managed By
Kevin Anderson
Technology Licensing Officer 612-624-8293
Patent Protection

Provisional Patent Application Filed


  • Therapeutic (alone or in combination) for cardiac arrhythmias
  • Research tool to knock-down miR-448 and or upregulate SCN5A
  • Cancer therapeutic (for cancers where miR-448 is relevant)

Technology Overview

Arrhythmic cardiomyopathy can cause severe problems including cardiac arrest and death. Unfortunately, many of the therapeutics to treat arrhythmias can actually have pro-arrhythmic side effects. This technology is an antagomir targeting miR-448 (anti-miR-448), a microRNA linked to the downregulation of the sodium channel SCN5A. Relieving the inhibition of miR-448 facilitates the upregulation of SCN5A, which is protective against arrhythmia, while bypassing the potential pro-arhythmic side-effects of existing therapies.

Phase of Development

TRL: 3
In vitro and in vivo testing.

Desired Partnerships

This technology is now available for:

  • License
  • Sponsored research
  • Co-development
Please contact Kevin Anderson to share your business’ needs and learn more.